-transparent.png){kind=logo}
The effects of betaxolol, a long-acting, lipid-soluble, cardioselective, beta-adrenergic antagonist on renal function have not been previously reported. The present study was designed to prospectively assess the acute and chronic antihypertensive, humoral, and renal response to betaxolol, administered once daily, to patients with essential hypertension. After a four-week placebo run-in period, 13 patients with essential hypertension were treated with betaxolol monotherapy for a total of eight months. Results indicate that blood pressure is reduced, and renal function remains stable. These findings are consistent with previous observations with other beta-adrenergic antagonists.
G P Reams, and
J H Bauer, and
A Lau
July 1979,
Klinische Wochenschrift,
G P Reams, and
J H Bauer, and
A Lau
October 1982,
European journal of clinical pharmacology,
G P Reams, and
J H Bauer, and
A Lau
December 1976,
Clinical science and molecular medicine. Supplement,
G P Reams, and
J H Bauer, and
A Lau
January 1989,
Fundamental & clinical pharmacology,
G P Reams, and
J H Bauer, and
A Lau
January 1976,
Verhandlungen der Deutschen Gesellschaft fur Innere Medizin,
G P Reams, and
J H Bauer, and
A Lau
January 1983,
American journal of nephrology,
G P Reams, and
J H Bauer, and
A Lau
September 1978,
Klinische Wochenschrift,
G P Reams, and
J H Bauer, and
A Lau
January 1991,
La Clinica terapeutica,
G P Reams, and
J H Bauer, and
A Lau
January 1975,
Verhandlungen der Deutschen Gesellschaft fur Innere Medizin,
G P Reams, and
J H Bauer, and
A Lau
August 1977,
Fukuoka igaku zasshi = Hukuoka acta medica,
